TriangleHEALTH PROFESSIONAL · SOURCE READING
Immunotherapy
Source: Melanoma Treatment (PDQ®)–Health Professional Version, National Cancer Institute.
Source updated: May 2, 2025 · Captured 2026-09-09.
Selected source text with whitespace normalised. This Triangle page is not an NCI PDQ summary.
Context: Treatment of Stage II Melanoma / Treatment Options for Stage II Melanoma / Adjuvant therapy
Adjuvant immunotherapy has demonstrated a recurrence-free survival (RFS) and DMFS benefit in patients with high-risk stage II melanoma that has been resected. These results led to FDA approval for the anti–programmed death-1 agent pembrolizumab. Data regarding potential OS benefit are still pending.
Continue within this section
Preserved source evidence · Not medical advice